25Apr 2017

THE IMPROVEMENT CHEST X-RAY AFTER CARVEDILOL THERAPHY IN HEART FAILURE DUE TO LEFT TO RIGHT SHUNT.

  • Department of Pediatric Faculty of Medicine Airlangga University Surabaya, East Java, Indonesia.
  • Airlangga University General Hospital Surabaya, East Java, Indonesia.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Heart failure due to left to right shunt congenital heart defect will increase pulmonary blood flow and cause volume overload. This condition activated the sympathetic nervous system and the renin-angiotensin-aldosteron system. Conventional therapy has not blocked the sympathetic system yet. Carvedilol, a novel non selective β-blocker, reduced mortality and hospitalization in adults with heart failure. Limited information was available about its use in children. Objective: To evaluate the effect of carvedilol on chest x-ray in children with heart failure due to left to right shunt congenital heart defect. Methods: A randomized, double-blind, placebo-controlled study was done. In addition to conventional therapy, patients were assigned to receive placebo or carvedilol. Carvedilol was initiated at a dose of 0.05 mg/kg/day, with a target dose of 0.2 mg/kg/day. Chest x-ray was done before-after treatment and evaluated for cardio-thoracic ratio and pulmonary vascularity. The data was analyzed using independent sample t-test and Chi-square test, with confidence interval 95%. Results: Of 30 patients, 15 in each group. The mean age was 57.6(SD 43.57) months, 19(63.3%) were boys. There were 21(70%) children with VSD and 9(30%) children with PDA. Compared to control group, children in the carvedilol group had a significant decrease of cardio-thoracic ratio(-2.94?2.34% versus -0.48?3.19%, p=0.023, CI 95%:-4.556 to-0.360). However, there was no significant change of pulmonary vascularity(p=0.153). Conclusion: Carvedilol decreased the cardio-thoracic ratio on chest x-ray, but did not improve the pulmonary vascularity in children with heart failure due to left to right shunt Congenital heart defect.

  1. Adatia, I., Kothari, S.S., Feinstein, J.A., 2010. Pulmonary hypertension associated with congenital heart disease. Chest, 137(6)(Suppl), 52S-61S.
  2. Atmosudigdo, I.S., 2007. Emergency Cardiovascular in Pediatric. In: Putra, S.T., Roebiono, P.S., Rahayuningsih, S.E., Wulandari, D.A., editor. Annual Pediatric Cardiology Meeting IV, 7-9 September 2007. Bandung: Pediatric cardiology Ascotiation, 96-100.
  3. Azeka,E., Ramires,J.A.F., Valler,C., Bocchi, E.A.,2002. Delisting of infant and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol,40,2034-8.
  4. Beggs, S., Thompson, A., Nash, R., Tompson, A., Peterson, G., 2009. Cardiac failure in children. Dalam: 17th Expert Committee on the Selection and Use of Essential Medicines, Maret 2009. Geneva: Expert Committee on the Selection and Use of Essential Medicines, 12-5.
  5. Blume, E.D., Canter, C.E., Spicer, R., Gauvreau, K., Colan, S., Jenkins, K.J.,dkk., 2006. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol, 27, 336-42.
  6. Bruns, L.A., Chrisant, M.K., Lamour, J.M., Shaddy, R.E., Pahl, E., Blume, E.D., dkk., 2001. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr, 138, 505-11.
  7. Burrows, F.A., Rabinovitch, M., 1985. Review Article:The pulmonary circulation in children with congenital heart disease: morphologic and morphometric considerations. Can Anaesth Soc J, 32, 364-73.
  8. Clark, A.L., Coats, A.J.S., 2000. Unrealibility of cardiothoracic ratio as marker of left ventricular impairment: comparison with radionuclide ventriculography and echocardiography. Postgrad Med J, 76, 289-291.
  9. Cohn, J., Ferrari, R., Sharpe, N., 2000. Cardiac remodelling, concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. JACC, 35(3), 569?82.
  10. Colucci, W.S., 1996. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation, 94, 2800-86.
  11. Dandona, P., Karne, R., Ghanim, H., Hamouda, W., Aljada, A., Magsino, C.H., 2000. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Am Heart J, 101, 122-4.
  12. Doughty, R.N., White, H.D., 2007. Carvedilol: usi in chronic heart failure. Expert Rev Cardiovasc Ther, 5(1), 21-31.
  13. Fujio, H., Nakamura, K., Matsubara, H., Kusano, K.F., Miyaji, K., Nagase, S., dkk., 2006. Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol, 47(2), 250-5. [Abstrak]
  14. Gachara, N.,Prabhakaran, S., Srinivas, S., Farzana, F., Krishnan, U., Shah, M.J., Efficacy and safety of carvedilol in infant with dilated cardiomyopathy: pre eliminary report. Indian Heart J, 53, 74-8.
  15. Giardini,A., Formigari, R., Bronzetti, G., Prandstraller, D., Donti, A., Bonvicini, M., ,2003. Modulation of neurohormonal activity after treatment of children with carvedilol. Cardiol Young, 13, 333-6.
  16. Horenstein, M.S., Ross, R.D., Singh, T.P., Epstein, M.L., 2002. Carvedilol reverses elevated pulmonary vascular resistance in a child with dilated cardiomyopathy. Pediatr Cardiol, 23, 100-2.
  17. Hsu, D.T., Pearson, G.D., 2009. Heart failure in children: part II: diagnosis, treatment, and future directions. Circ Heart Fail, 2, 490-8.
  18. Ishibashi, N., Park, I., Waragai, T., Yoshikawa, T., Murakami, Y., Mori, K., dkk., 2011. Effect of carvedilol on heart failure in patients with functionally univentricular heart. Circ J, 75, 1394-9.
  19. Komajda, M., Lutiger, B., Madeira, H., Thygesen, K., Bobbio, M., Hildebrandt, P., 2004. Tolerability of carvedilol and ACE-inhibitor in mild heart failure. Result of CARMEN (Carvedilol ACE-inhibitor remodelling mild CHF evaluation). Eur J Heart Failure, 6, 467-75.
  20. Kukin, M.L., Kalman, J., Charney, R.H., Levy, D.K., Buchholz-Varley, C., Ocampo, O.N.,, 1999. Prospective, randomized comparison of effect of long term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction,and oxidative stress in heart failure. Circulation, 99, 2645-51.
  21. L?er, S., Mir, T.S., Behn, F., Eiselt, M., Scholz, H., Venszke, A., dkk., 2002. Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters. Am Heart J, 143, 916-22.
  22. Landzberg, M.J., 2007. Congenital heart disease associated pulmonary arterial hypertension.Clin Chest Med, 28, 243-53.
  23. Li, R., Yi, Q.J., Qian, Y.R., Liu, X.Y., Zhong, J.R., Bai, Y.H., dkk., 2008. Preliminary study on the effect of carvedilol on children with primary endocardial fibroelastosis. Zhonghua Er Ke Za Zhi, 46(9), 684-7. [Abstract]
  24. Madriago, E., Silberbach, M., 2010. Heart failure in infants and children. Pediatr Rev, 31, 4-12.
  25. Maurer, M.S., Sackner-Bernstein, J.D., Rumbarger, L.E., Yushak, M., King, D.L., Burkhoff, D., 2009. Mechanism underlying improvement in ejection fraction with carvedilol in heart failure. Circ Heart Fail, 2, 189-96.
  26. Nakamura, K., Kusano, K., Nakamura, Y., Kakishita, M., Ohta, K., Nagase, S., , 2002. Carvedilol decrease elevated oxidative stress in human failing myocardium. Circulation, 105, 2867-71.
  27. Nishiyama, M., Park, I.S., Yoshikawa, T., Hatai, Y., Ando, M., Takahashi, Y., dkk., 2009. Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease. Heart Vessels, 24,187-92.
  28. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.C., Fowler, M.B., Gilbert, E.M., dkk., 1996. The effect of carvedilol on morbity and mortality in patients with chronic heart failure. N Engl J Med, 334, 1349-55.
  29. Packer, M., Antonopoulos, G.V., Berlin, J.A., Chittams, J., Konstam, M.A., Udelson, J.E., 2002. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation, 106, 2194-9.
  30. Roig, E., 2006. Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure. Eur Heart J, 8(suppl E), 12-7.
  31. Rusconi, P., Gomez-Marin, O., Rossique-Gonzalez, M., Redha, E., Marin, J.R., Lon-Young, M., , 2004. Carvedilol in children with cardiomyophaty: 3-year experience at a single institution. J Heart Lung Transplant, 23, 832-8.
  32. Satou, G.M., Lacro, R.V., Chung, T., Gauvreau, K., Jenkins, K.J., 2001. Heart size on chest x-ray as a predictor of cardiac enlargement by echocardiography in children. Pediatr Cardiol, 22, 218-22.
  33. Shaddy, R.E.,Boecek, M.M., Hsu, D.T., Boucek, R.J., Canter, E.E., Mohony, L., dkk., 2007. Carvedilol for children and adolescents with heart failure. A rondomized controlled trial. JAMA, 298(10), 1171-9.
  34. Tumkosit, M., Yingyong, N., Mahayasnond, A., Choo, K.S., Goo, H.W., 2012. Accuracy of chest radiography for evaluating significantly abnormal pulmonary vascularity in children with congenital heart disease. Int J Cardiovasc Imaging, DOI 10.1007/s10554-012-0073-x.
  35. William, R.V., Tani, L.,Y., Shaddy, R.E., 2002. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J Heart Lung Transplant, 21, 906-9.

[Mahrus A Rahman, Enny Zuraedah, Taufiq Hidayat, Alit Utamayasa and Teddy Ontoseno. (2017); THE IMPROVEMENT CHEST X-RAY AFTER CARVEDILOL THERAPHY IN HEART FAILURE DUE TO LEFT TO RIGHT SHUNT. Int. J. of Adv. Res. 5 (Apr). 1134-1140] (ISSN 2320-5407). www.journalijar.com

TAUFIQ HIDAYAT
Co-auhor

DOI:

Article DOI: 10.21474/IJAR01/3925      
DOI URL: http://dx.doi.org/10.21474/IJAR01/3925

Download Full Paper

Download PDF No. of Downloads: 20 | No. of Views: 167